Clinical Trial Update: Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating the efficacy and safety of a topical cannabidiol product (Canvert-M) for migraine attacks. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Canvert-M (cannabidiol)

Snippet

Sponsor: Alasht Pharmed | Conditions: Migraine Disorders | Phase 4 | Status: RECRUITING